@prefix biolink: <https://w3id.org/biolink/vocab/> .
@prefix infores: <https://w3id.org/biolink/infores/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix npx: <http://purl.org/nanopub/x/> .
@prefix orcid: <https://orcid.org/> .
@prefix pav: <http://purl.org/pav/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix sub: <http://purl.org/np/RA29A1XL8_FwRpUAbDdjhoL1b2I_tcnXRDStd3NBuWt0w#> .
@prefix this: <http://purl.org/np/RA29A1XL8_FwRpUAbDdjhoL1b2I_tcnXRDStd3NBuWt0w> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
sub:Head {
   this: np:hasAssertion sub:assertion ;
    np:hasProvenance sub:provenance ;
    np:hasPublicationInfo sub:pubinfo ;
    a np:Nanopublication .
}
sub:assertion {
   <http://identifiers.org/hmdb/HMDB0303394> a biolink:ChemicalEntity ;
    rdfs:label "Dextroamphetamine sulfate" ;
    biolink:category biolink:ChemicalEntity .
  <http://purl.obolibrary.org/obo/MONDO_0005302> a biolink:DiseaseOrPhenotypicFeature ;
    rdfs:label "Attention Deficit Disorder with Hyperactivity" ;
    biolink:category biolink:DiseaseOrPhenotypicFeature .
  sub:_1 rdf:object <http://purl.obolibrary.org/obo/MONDO_0005302> ;
    rdf:predicate biolink:treats ;
    rdf:subject <http://identifiers.org/hmdb/HMDB0303394> ;
    a biolink:Association ;
    biolink:aggregator_knowledge_source infores:knowledge-collaboratory ;
    biolink:category biolink:Association ;
    biolink:publications <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bed3c03f4-2829-423f-a595-dc09c9cc0e40> .
}
sub:provenance {
   sub:assertion prov:generatedAtTime "2022-10-28T09:01:37.010437"^^xsd:dateTime ;
    prov:wasAttributedTo orcid:0000-0003-4727-9435 ;
    prov:wasQuotedFrom "Dextroamphetamine sulfate tablets are indicated in: Narcolepsy and Attention Deficit Disorder with Hyperactivity: As an integral part of a total treatment program that typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in pediatric patients (ages 3 years to 16 years)" .
  biolink: pav:version "2.3.0" .
}
sub:pubinfo {
   sub:sig npx:hasAlgorithm "RSA" ;
    npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCTQs+mANCSHWhIW/YPio468UdGNHsPvADpjfaW8um/v2L4AoDIANginfoU65VNbPT5D0ADt1y0uFNne3VEMr9Y+I2HFaz6IKj+LdYMJk6VUf5WJoImRHIX6BZQwcUc22CbTBFYxvqvp3UmmHrCrhLIZjDSyutExK3tOTRoMDjGowIDAQAB" ;
    npx:hasSignature "PtuyKiasP0PHfxPxu8SFpH2OwHHta6EZFZr+U5d8keOJ2y/Q25cqdaOlkMzPQq8eS2CPa/6ce7c3YYgNUjKVO5WeofE3k0R6mmP2yqNVFhIHEZOE370XIBgtMQGRFqHZnW2MR+m1afqfqjEuPjbA+kAPrlZUYprRaUp/tVM4cwM=" ;
    npx:hasSignatureTarget this: .
  this: prov:generatedAtTime "2022-10-28T09:01:37.010437"^^xsd:dateTime ;
    prov:wasAttributedTo orcid:0000-0003-4727-9435 .
}